STOCK TITAN

Corcept Therapeutics Incorporated - CORT STOCK NEWS

Welcome to our dedicated page for Corcept Therapeutics Incorporated news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics Incorporated stock.

Corcept Therapeutics Inc. (symbol: CORT) is a pioneering pharmaceutical company focused on the discovery and development of medications that modulate the effects of cortisol to treat severe metabolic, oncologic, and neuropsychiatric disorders. Since its inception, Corcept has dedicated itself to understanding and mitigating the adverse effects of excess cortisol, which plays a role in a variety of diseases.

The company has made significant strides in this field by developing over 300 proprietary molecules. These compounds competitively block the glucocorticoid receptor (GR) without affecting the progesterone receptor. Scientific studies suggest that GR antagonism may help treat conditions such as post-traumatic stress disorder, mild cognitive impairment, Alzheimer's disease, and alcoholism.

Corcept's flagship product, mifepristone, is already making an impact in the market. Additionally, the company continues to advance the most promising compounds from its extensive pipeline into clinical trials to assess their potential in mitigating the effects of excess cortisol and treating serious, sometimes life-threatening conditions.

Corcept's recent achievements include a series of successful clinical trials and partnerships that have bolstered its position in the pharmaceutical industry. Financially, the company is on stable ground, allowing it to invest further in research and development to expand its portfolio of effective treatments.

As a commercial-stage company, Corcept Therapeutics is committed to bringing innovative treatments to market, guided by a deep understanding of cortisol’s role in various diseases. Investors and healthcare professionals alike are keenly watching Corcept for its continued contributions to medical science and patient care.

For the latest updates on Corcept Therapeutics, including performance, events, and developments, please visit their official website or contact their investor relations team.

Rhea-AI Summary

Corcept Therapeutics announced results from the prevalence phase of their CATALYST clinical trial at the American Diabetes Association’s 84th Scientific Sessions.

The trial enrolled 1,055 patients with difficult-to-control type 2 diabetes across 36 U.S. sites, making it the largest study of its kind. The results showed a 24% prevalence rate of hypercortisolism among these patients, a higher figure than previously assumed.

Hypercortisolism was notably common in patients with cardiovascular issues and those needing multiple medications for diabetes and hypertension control.

This new data may lead to better diagnosis and treatment strategies for hypercortisolism, a serious condition often overlooked in type 2 diabetes management.

Details of the treatment phase, where eligible patients received either Korlym or a placebo, are expected by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
-
Rhea-AI Summary

Corcept Therapeutics (NASDAQ: CORT) announced that results from the Phase 3 GRACE trial of relacorilant, a selective cortisol modulator for treating hypercortisolism (Cushing’s syndrome), will be presented at two major conferences in June 2024. The presentations will take place at the Endocrine Society (ENDO) annual meeting in Boston on June 3, and at the Heart in Diabetes (HiD) conference in Philadelphia on June 7. Key findings will be shared by Dr. Rosario Pivonello and Dr. Ralph DeFronzo, highlighting the impact of relacorilant on hypertension and hyperglycemia. Detailed results will be accessible on Corcept’s website post-events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
-
Rhea-AI Summary

Corcept Therapeutics (NASDAQ: CORT) announced positive results from its Phase 3 GRACE trial of relacorilant for treating hypercortisolism (Cushing’s syndrome). The trial met its primary endpoint, showing significant improvements in hypertension, hyperglycemia, and other symptoms. In the randomized withdrawal phase, patients receiving relacorilant had a notably lower loss of blood pressure control compared to those on placebo (odds ratio: 0.17; p-value: 0.02). The drug was well-tolerated, with no significant safety differences observed. Corcept plans to submit a New Drug Application in Q3, with additional data presentations scheduled for June.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.86%
Tags
Rhea-AI Summary

Corcept Therapeutics Incorporated reported strong financial results for the first quarter of 2024, with a revenue of $146.8 million, a 39% increase from the same period in 2023. The company raised its 2024 revenue guidance to $620 - $650 million and reported a net income per common share of $0.25. Corcept continues to focus on developing medications for various disorders by modulating the effects of cortisol. The company highlighted record numbers of new prescribers and patients for its drug Korlym in the first quarter, showcasing its growing presence in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
-
Rhea-AI Summary

Corcept Therapeutics Incorporated has completed enrollment in the Phase 4 CATALYST trial, the largest study ever conducted to establish the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. Approximately 25% of the over 1,000 patients enrolled were identified as having hypercortisolism, a higher rate than previously assumed. Final prevalence data will be shared at the American Diabetes Association’s 84th Scientific Sessions in June, with treatment data expected by year-end. The findings from CATALYST aim to improve the identification and treatment of patients with hypercortisolism.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
-
Rhea-AI Summary
Corcept Therapeutics (NASDAQ: CORT) will unveil its first quarter financial results and share a corporate update on May 1, 2024. A conference call is scheduled for 5:00 p.m. Eastern Time. Participants need to register in advance to receive the dial-in number and access PIN.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
Rhea-AI Summary
Corcept Therapeutics announces positive results from the open-label portion of the pivotal Phase 3 GRACE trial for relacorilant in patients with Cushing’s syndrome. The trial showed significant improvements in hypertension, hyperglycemia, and other key endpoints without adverse effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
-
Rhea-AI Summary
Corcept Therapeutics Incorporated completes enrollment in Phase 2 DAZALS trial for ALS patients, testing dazucorilant's efficacy in improving motor performance and quality of life. The study enrolled 249 patients and is expected to provide data by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
-
Rhea-AI Summary
Corcept Therapeutics (CORT) completes enrollment in ROSELLA Phase 3 trial for ovarian cancer treatment with relacorilant and nab-paclitaxel, aiming to improve patient outcomes. The trial mirrors positive Phase 2 results, showing potential for relacorilant to enhance survival rates. Progression-free survival data expected by year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.85%
Tags
Rhea-AI Summary
Corcept Therapeutics (CORT) completes enrollment in Phase 3 trial for relacorilant in patients with Cushing’s syndrome, targeting serious cardiometabolic comorbidities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags

FAQ

What does Corcept Therapeutics Inc. do?

Corcept Therapeutics Inc. develops medications that modulate cortisol to treat severe metabolic, oncologic, and neuropsychiatric disorders.

What is the primary focus of Corcept Therapeutics' research?

The primary focus is on mitigating the effects of excess cortisol, which can cause various metabolic, oncologic, and psychiatric diseases.

What are some of the conditions Corcept's products aim to treat?

Conditions include post-traumatic stress disorder, mild cognitive impairment, Alzheimer's disease, and alcoholism.

What is mifepristone?

Mifepristone is Corcept Therapeutics' flagship product used to block the effects of excess cortisol.

How many proprietary molecules has Corcept developed?

Corcept has developed over 300 proprietary molecules that competitively block the glucocorticoid receptor.

Does Corcept Therapeutics have any ongoing clinical trials?

Yes, Corcept continues to advance promising compounds into clinical trials to evaluate their efficacy in treating cortisol-related conditions.

Are there any recent achievements by Corcept Therapeutics?

Recent achievements include successful clinical trials and strategic partnerships that enhance their market position.

What is the financial condition of Corcept Therapeutics?

Corcept is financially stable, which supports its ongoing research and development efforts.

How can I get the latest updates on Corcept Therapeutics?

Visit Corcept's official website or contact their investor relations team for the latest updates.

What role does cortisol play in diseases?

Abnormal levels and release of cortisol are linked to various metabolic, oncologic, and psychiatric diseases.

Corcept Therapeutics Incorporated

Nasdaq:CORT

CORT Rankings

CORT Stock Data

3.53B
104.11M
11.39%
91.97%
20.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
MENLO PARK